Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series
DOI:
https://doi.org/10.2340/actadv.v105.40952Keywords:
Alemtuzumab, Brentuximab Vedotin, Mogamulizumab, Mycosis Fungoides, cutaneous T-cell lymphoma, Sezary syndromeAbstract
Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphomas. Early stages are often controlled with skin-directed therapy, such as topical corticosteroids, topical chlormethine gel, or UV therapy, whereas advanced stages often warrant a more aggressive approach with systemic antibody targeted therapy including mogamulizumab, brentuximab vedotin, or alemtuzumab. A retrospective cohort case series of 27 patients from Aarhus University Hospital, Denmark is presented, evaluating real-world outcomes of patients with cutaneous T-cell lymphomas treated with intravenous systemic targeted therapies from 2013 to 2023. The median age was 72 and the majority had Sézary syndrome or mycosis fungoides. All patients had relapsed/refractory advanced stage cutaneous T-cell lymphoma. Six patients received mogamulizumab, 12 patients received brentuximab vedotin, and 15 patients received alemtuzumab. Six patients received more than 1 of the systemic targeted treatments. Overall response rates were 78% for mogamulizumab, 65% for brentuximab vedotin, and 61% for alemtuzumab. Median time to progression was 2.5, 4, and 11 months, respectively. In conclusion, this paper offers a unique perspective on the complexities of clinical practice when managing advanced-stage cutaneous T-cell lymphomas and demonstrates the effectiveness of the therapies described, with particular emphasis on the promising results observed with alemtuzumab administered in a low-dose protocol.
Downloads
References
Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730–4739.
https://doi.org/10.1200/JCO.2009.27.7665 DOI: https://doi.org/10.1200/JCO.2009.27.7665
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv 2021; 5: 5098–5106.
https://doi.org/10.1182/bloodadvances.2021004710 DOI: https://doi.org/10.1182/bloodadvances.2021004710
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192–1204.
https://doi.org/10.1016/S1470-2045(18)30379-6 DOI: https://doi.org/10.1016/S1470-2045(18)30379-6
Fujimura T, Amagai R, Kambayashi Y, Aiba S. Topical and systemic formulation options for cutaneous T cell lymphomas. Pharmaceutics 2021; 13.
https://doi.org/10.3390/pharmaceutics13020200 DOI: https://doi.org/10.3390/pharmaceutics13020200
Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, et al. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry. J Eur Acad Dermatol Venereol 2023; 37: 57–64.
https://doi.org/10.1111/jdv.18563 DOI: https://doi.org/10.1111/jdv.18563
Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012; 4: 117ra117.
https://doi.org/10.1126/scitranslmed.3003008 DOI: https://doi.org/10.1126/scitranslmed.3003008
Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012; 53: 789–795.
https://doi.org/10.3109/10428194.2011.629701 DOI: https://doi.org/10.3109/10428194.2011.629701
Weaver TA, Kirk AD. Alemtuzumab. Transplantation 2007; 84: 1545–1547.
https://doi.org/10.1097/01.tp.0000296680.75175.67 DOI: https://doi.org/10.1097/01.tp.0000296680.75175.67
Ravandi F, O’Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24: 718–725.
https://doi.org/10.1080/07357900600981414 DOI: https://doi.org/10.1080/07357900600981414
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703–1714.
https://doi.org/10.1182/blood-2018-11-881268 DOI: https://doi.org/10.1182/blood-2018-11-881268
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713–1722.
https://doi.org/10.1182/blood-2007-03-055749 DOI: https://doi.org/10.1182/blood-2007-03-055749
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479–484.
https://doi.org/10.1182/blood-2006-10-054601 DOI: https://doi.org/10.1182/blood-2006-10-054601
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022; 140: 419–437.
https://doi.org/10.1182/blood.2021012057 DOI: https://doi.org/10.1182/blood.2021012057
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, et al. Effectiveness of mogamulizumab in patients with mycosis fungoides or Sézary syndrome: a multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37: 1777–1784.
https://doi.org/10.1111/jdv.19134 DOI: https://doi.org/10.1111/jdv.19134
de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 2014; 170: 720–724.
https://doi.org/10.1111/bjd.12690 DOI: https://doi.org/10.1111/bjd.12690
Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. Br J Dermatol 2018; 179: 1322–1328.
https://doi.org/10.1111/bjd.17073 DOI: https://doi.org/10.1111/bjd.17073
Scarisbrick JJ. Infections in mycosis fungoides and Sézary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done? Br J Dermatol 2018; 179: 1243–1244.
https://doi.org/10.1111/bjd.17194 DOI: https://doi.org/10.1111/bjd.17194
Published
How to Cite
License
Copyright (c) 2025 Signe Hedebo, Martin B. Pedersen, Lise M. Lindahl, Aska Drjlevic-Nielsen, Claus Johansen, Francesco d'Amore, Lars Iversen, Rikke Bech
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
